ARDENT HEALTH INC (ARDT) Stock Fundamental Analysis
USA - NYSE:ARDT - US03980N1072 - Common Stock
14.53 USD
-0.14 (-0.95%)
Taking everything into account, ARDT scores 5 out of 10 in our fundamental rating. ARDT was compared to 100 industry peers in the Health Care Providers & Services industry. ARDT has only an average score on both its financial health and profitability. ARDT may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
ARDT had positive earnings in the past year.
In the past year ARDT had a positive cash flow from operations.
1.2 Ratios
With a decent Return On Assets value of 5.07%, ARDT is doing good in the industry, outperforming 78.00% of the companies in the same industry.
ARDT has a better Return On Equity (20.31%) than 88.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.74%, ARDT is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
ARDT had an Average Return On Invested Capital over the past 3 years of 5.96%. This is below the industry average of 9.42%.
The last Return On Invested Capital (8.74%) for ARDT is above the 3 year average (5.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.07% | ||
| ROE | 20.31% | ||
| ROIC | 8.74% |
ROA(3y)3.2%
ROA(5y)N/A
ROE(3y)18.73%
ROE(5y)N/A
ROIC(3y)5.96%
ROIC(5y)N/A
1.3 Margins
ARDT's Profit Margin of 4.11% is fine compared to the rest of the industry. ARDT outperforms 74.00% of its industry peers.
ARDT's Profit Margin has improved in the last couple of years.
The Operating Margin of ARDT (6.97%) is better than 69.00% of its industry peers.
ARDT's Operating Margin has improved in the last couple of years.
ARDT has a better Gross Margin (57.76%) than 79.00% of its industry peers.
In the last couple of years the Gross Margin of ARDT has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.97% | ||
| PM (TTM) | 4.11% | ||
| GM | 57.76% |
OM growth 3Y3%
OM growth 5YN/A
PM growth 3Y3.64%
PM growth 5YN/A
GM growth 3Y2.83%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ARDT is destroying value.
ARDT has more shares outstanding than it did 1 year ago.
ARDT has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.22 indicates that ARDT is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.22, ARDT is in line with its industry, outperforming 49.00% of the companies in the same industry.
The Debt to FCF ratio of ARDT is 10.26, which is on the high side as it means it would take ARDT, 10.26 years of fcf income to pay off all of its debts.
ARDT has a Debt to FCF ratio (10.26) which is in line with its industry peers.
A Debt/Equity ratio of 0.87 indicates that ARDT is somewhat dependend on debt financing.
ARDT's Debt to Equity ratio of 0.87 is in line compared to the rest of the industry. ARDT outperforms 41.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | 10.26 | ||
| Altman-Z | 2.22 |
ROIC/WACC0.99
WACC8.86%
2.3 Liquidity
A Current Ratio of 2.13 indicates that ARDT has no problem at all paying its short term obligations.
The Current ratio of ARDT (2.13) is better than 77.00% of its industry peers.
ARDT has a Quick Ratio of 2.00. This is a normal value and indicates that ARDT is financially healthy and should not expect problems in meeting its short term obligations.
ARDT has a Quick ratio of 2.00. This is in the better half of the industry: ARDT outperforms 77.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.13 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
ARDT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 314.38%, which is quite impressive.
Measured over the past years, ARDT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.75% on average per year.
ARDT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.29%.
The Revenue has been growing slightly by 7.00% on average over the past years.
EPS 1Y (TTM)314.38%
EPS 3Y13.75%
EPS 5YN/A
EPS Q2Q%52.94%
Revenue 1Y (TTM)10.29%
Revenue growth 3Y7%
Revenue growth 5YN/A
Sales Q2Q%11.85%
3.2 Future
The Earnings Per Share is expected to grow by 21.62% on average over the next years. This is a very strong growth
Based on estimates for the next years, ARDT will show a small growth in Revenue. The Revenue will grow by 6.44% on average per year.
EPS Next Y52.55%
EPS Next 2Y26.02%
EPS Next 3Y21.62%
EPS Next 5YN/A
Revenue Next Year8.59%
Revenue Next 2Y6.75%
Revenue Next 3Y6.44%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ARDT is valuated reasonably with a Price/Earnings ratio of 8.12.
95.00% of the companies in the same industry are more expensive than ARDT, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.13. ARDT is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 7.44, which indicates a rather cheap valuation of ARDT.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ARDT indicates a rather cheap valuation: ARDT is cheaper than 97.00% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of ARDT to the average of the S&P500 Index (22.35), we can say ARDT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.12 | ||
| Fwd PE | 7.44 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ARDT is valued cheaper than 94.00% of the companies in the same industry.
65.00% of the companies in the same industry are more expensive than ARDT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.23 | ||
| EV/EBITDA | 4.58 |
4.3 Compensation for Growth
ARDT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ARDT may justify a higher PE ratio.
ARDT's earnings are expected to grow with 21.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.15
PEG (5Y)N/A
EPS Next 2Y26.02%
EPS Next 3Y21.62%
5. Dividend
5.1 Amount
ARDT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:ARDT (11/6/2025, 10:01:25 AM)
14.53
-0.14 (-0.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners73.82%
Inst Owner Change-0.23%
Ins Owners1.98%
Ins Owner Change-0.01%
Market Cap2.08B
Revenue(TTM)6.20B
Net Income(TTM)254.86M
Analysts81.11
Price Target19.81 (36.34%)
Short Float %2.65%
Short Ratio8.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.13%
Min EPS beat(2)43.05%
Max EPS beat(2)71.2%
EPS beat(4)3
Avg EPS beat(4)36.54%
Min EPS beat(4)-44.28%
Max EPS beat(4)76.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.16%
Min Revenue beat(2)-2.01%
Max Revenue beat(2)4.33%
Revenue beat(4)2
Avg Revenue beat(4)1.58%
Min Revenue beat(4)-2.11%
Max Revenue beat(4)6.1%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.19%
PT rev (3m)-5.1%
EPS NQ rev (1m)-1.07%
EPS NQ rev (3m)-39.85%
EPS NY rev (1m)-0.16%
EPS NY rev (3m)-3.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.88%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.12 | ||
| Fwd PE | 7.44 | ||
| P/S | 0.34 | ||
| P/FCF | 19.23 | ||
| P/OCF | 6.89 | ||
| P/B | 1.66 | ||
| P/tB | 6.93 | ||
| EV/EBITDA | 4.58 |
EPS(TTM)1.79
EY12.32%
EPS(NY)1.95
Fwd EY13.44%
FCF(TTM)0.76
FCFY5.2%
OCF(TTM)2.11
OCFY14.52%
SpS43.31
BVpS8.77
TBVpS2.1
PEG (NY)0.15
PEG (5Y)N/A
Graham Number18.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.07% | ||
| ROE | 20.31% | ||
| ROCE | 10.43% | ||
| ROIC | 8.74% | ||
| ROICexc | 10.05% | ||
| ROICexgc | 13.67% | ||
| OM | 6.97% | ||
| PM (TTM) | 4.11% | ||
| GM | 57.76% | ||
| FCFM | 1.74% |
ROA(3y)3.2%
ROA(5y)N/A
ROE(3y)18.73%
ROE(5y)N/A
ROIC(3y)5.96%
ROIC(5y)N/A
ROICexc(3y)6.85%
ROICexc(5y)N/A
ROICexgc(3y)9.47%
ROICexgc(5y)N/A
ROCE(3y)7.12%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y3%
OM growth 5YN/A
PM growth 3Y3.64%
PM growth 5YN/A
GM growth 3Y2.83%
GM growth 5YN/A
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | 10.26 | ||
| Debt/EBITDA | 1.87 | ||
| Cap/Depr | 129.12% | ||
| Cap/Sales | 3.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 51.85% | ||
| Profit Quality | 42.43% | ||
| Current Ratio | 2.13 | ||
| Quick Ratio | 2 | ||
| Altman-Z | 2.22 |
F-Score8
WACC8.86%
ROIC/WACC0.99
Cap/Depr(3y)111.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.88%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)314.38%
EPS 3Y13.75%
EPS 5YN/A
EPS Q2Q%52.94%
EPS Next Y52.55%
EPS Next 2Y26.02%
EPS Next 3Y21.62%
EPS Next 5YN/A
Revenue 1Y (TTM)10.29%
Revenue growth 3Y7%
Revenue growth 5YN/A
Sales Q2Q%11.85%
Revenue Next Year8.59%
Revenue Next 2Y6.75%
Revenue Next 3Y6.44%
Revenue Next 5YN/A
EBIT growth 1Y87.99%
EBIT growth 3Y10.2%
EBIT growth 5YN/A
EBIT Next Year68.59%
EBIT Next 3Y25.08%
EBIT Next 5YN/A
FCF growth 1Y51.28%
FCF growth 3Y152.66%
FCF growth 5YN/A
OCF growth 1Y42.1%
OCF growth 3Y28.95%
OCF growth 5YN/A
ARDENT HEALTH INC / ARDT FAQ
Can you provide the ChartMill fundamental rating for ARDENT HEALTH INC?
ChartMill assigns a fundamental rating of 5 / 10 to ARDT.
What is the valuation status of ARDENT HEALTH INC (ARDT) stock?
ChartMill assigns a valuation rating of 9 / 10 to ARDENT HEALTH INC (ARDT). This can be considered as Undervalued.
Can you provide the profitability details for ARDENT HEALTH INC?
ARDENT HEALTH INC (ARDT) has a profitability rating of 6 / 10.
What is the expected EPS growth for ARDENT HEALTH INC (ARDT) stock?
The Earnings per Share (EPS) of ARDENT HEALTH INC (ARDT) is expected to grow by 52.55% in the next year.